Skip to content

L2Be Pharma: what changed

BE 0764.501.936NACE 74.999, Other professional, scientific and technical activitiesOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€14,987
2024 · €22,063-€7,075
Equity
€57,221
2024 · €57,221
Cash
€123,358
2024 · €100,973+€22,385
Balance sheet total
€153,570
2024 · €147,948+€5,621

Largest movements

2024 to 2025
Assets
  • Cash +€22,385

    up €22,385 (+22.2%), from €100,973 to €123,358

    mainly Net result for the year (+€14,987) and Other debts (+€14,425)

  • Deferred charges and accrued income -€11,954

    down €11,954 (-88.3%), from €13,544 to €1,590

  • Receivables within one year -€4,810

    down €4,810 (-14.4%), from €33,432 to €28,622

    of which Trade receivables: -€11,833

Equity and liabilities
  • Other debts +€14,425

    up €14,425 (+25.2%), from €57,188 to €71,614

  • Tax, wage and social debts -€8,355

    down €8,355 (-28.7%), from €29,075 to €20,720

    of which Taxes: -€8,355

Income statement
  • Other operating charges +€14,685

    up €14,685 (+1,947%), from €754 to €15,439

  • Gross operating margin +€4,231

    up €4,231 (+13.0%), from €32,550 to €36,781

  • Taxes -€2,484

    down €2,484 (-33.6%), from €7,386 to €4,902

  • Financial income +€839

    first reported in 2025, at €839

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result.

Result 2024 €22,063
Gross operating margin +€4,231
Depreciation +€161
Other operating charges -€14,685
Financial income +€839
Financial charges -€106
Taxes +€2,484
Result 2025 €14,987
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€37,373
Investment €0
Financing -€14,987
Cash 2024 €100,973
Net result for the year +€14,987
Receivables within one year +€4,810
Deferred charges and accrued income +€11,954
Trade debts -€449
Tax, wage and social debts -€8,355
Other debts +€14,425
Contributions, distributions and other -€14,987
Cash 2025 €123,358
brings cash intakes cash out
Every line side by side 32 lines
Line Code 2024 2025 Change %
Total assets 20/58 €147,948 €153,570 +€5,621 +3.8%
Current assets 29/58 €147,948 €153,570 +€5,621 +3.8%
Amounts receivable within one year 40/41 €33,432 €28,622 -€4,810 -14.4%
Trade receivables 40 €33,432 €21,599 -€11,833 -35.4%
Other amounts receivable 41 - €7,023 +€7,023
Cash at bank and in hand 54/58 €100,973 €123,358 +€22,385 +22.2%
Deferred charges and accrued income 490/1 €13,544 €1,590 -€11,954 -88.3%
Total equity and liabilities 10/49 €147,948 €153,570 +€5,621 +3.8%
Equity 10/15 €57,221 €57,221 = 0.0%
Contributions 10/11 €5,000 €5,000 = 0.0%
Reserves 13 €52,221 €52,221 = 0.0%
Distributable reserves 133 €52,221 €52,221 = 0.0%
Amounts payable 17/49 €90,728 €96,349 +€5,621 +6.2%
Amounts payable within one year 42/48 €90,728 €96,349 +€5,621 +6.2%
Trade debts 44 €4,465 €4,016 -€449 -10.1%
Suppliers 440/4 €4,465 €4,016 -€449 -10.1%
Taxes, remuneration and social security 45 €29,075 €20,720 -€8,355 -28.7%
Taxes 450/3 €25,775 €17,420 -€8,355 -32.4%
Remuneration and social security 454/9 €3,300 €3,300 = 0.0%
Other amounts payable 47/48 €57,188 €71,614 +€14,425 +25.2%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €161 - -€161
Other operating charges 640/8 €754 €15,439 +€14,685 +1,947%
Gross operating margin 9900 €32,550 €36,781 +€4,231 +13.0%
Operating profit (loss) 9901 €31,634 €21,342 -€10,293 -32.5%
Financial income 75/76B - €839 +€839
Recurring financial income 75 - €839 +€839
Financial charges 65/66B €2,186 €2,292 +€106 +4.8%
Recurring financial charges 65 €2,186 €2,292 +€106 +4.8%
Profit (loss) for the period before taxes 9903 €29,448 €19,889 -€9,559 -32.5%
Income taxes 67/77 €7,386 €4,902 -€2,484 -33.6%
Profit (loss) for the period 9904 €22,063 €14,987 -€7,075 -32.1%
Profit (loss) for the period to be appropriated 9905 €22,063 €14,987 -€7,075 -32.1%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Value of the equity

Indication, not a valuation or advice
€123,785 to €161,855

Midpoint €139,648 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate. Change the assumptions and the value follows.

Adjusted equity €57,221
Capitalised earnings €190,350 to €266,490
Indication €123,785 to €161,855

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€57,221
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€57,221

Capitalised earnings

net result for the year (9904)
2025
€14,987
2024
€22,063
2023
€42,897
2022
€5,421
2021
€46,799
Average result
€26,649
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€190,350 / €222,075 / €266,490

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 20 November 2026 via checked.be.